&w=3840&q=100)
Hypertension, anti allergy meds among 196 drugs flagged by CDSCO as NSQ
The Central Drugs Standard Control Organisation (CDSCO) has labelled batches of 196 drugs and formulations as not of standard quality (NSQ) in its monthly quality review for April 2025.
The NSQ list includes a fixed drug combination (FDC) of teneligliptin and metformin hydrochloride, which is used to treat hypertension, and antibacterials such as cefpodoxime proxetil tablets.
The list also includes batches of painkillers containing combinations of paracetamol with nimesulide and aceclofenac, as well as cough syrups and anti-allergy formulations.
Of the 196 drug samples found NSQ for April 2025, 60 were identified by central drug laboratories, while 136 were tested at state laboratories.
The country's apex drug regulator also flagged one batch of Deca-Durabolin injections, which are used to manage post-menopausal osteoporosis and anaemia, as spurious. While the CDSCO has named the brand for which it found spurious samples, it has not named the drug manufacturer.
The health ministry said the spurious drug sample was identified from Bihar, adding that it was manufactured by an unauthorised entity using the brand name owned by another company.
'The matter is under investigation and action will be taken according to rules,' the ministry note added.
Spurious drugs are fake or counterfeit medicines that falsely claim to be genuine, often containing incorrect, contaminated, or no active ingredients—making them ineffective and potentially harmful to patients.
'The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug,' the CDSCO alert added.
As part of continuous regulatory surveillance, the CDSCO picks up drug samples from sales or distribution points, analyses them, and displays a list of spurious drugs on its portal on a monthly basis.
'This action of identifying NSQ and spurious medicines is taken on a regular basis in collaboration with state regulators to ensure that these drugs are identified and removed from the market,' the NSQ alert stated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
3 days ago
- Business Standard
AMR crisis: Centre asks states to monitor antibiotic use in animals
In an effort to tackle the growing problem of antimicrobial resistance (AMR), which is estimated to claim 2 million lives in India by 2050, the Central Drugs Standard Control Organisation (CDSCO) has asked all state drug controllers to support the development of an antimicrobial use (AMU) reporting framework. The aim is to strengthen monitoring of antibiotic use in animals. For the first time, a joint working group will be formed, comprising representatives from the CDSCO, state licensing authorities (SLAs), and the Department of Animal Husbandry and Dairying (DAHD), to facilitate the implementation of the framework. Officials in the know said the framework will focus on the systematic collection of data on the sale, manufacture, and import of antibiotics for veterinary use. This move follows the Centre's release of the Standard Veterinary Treatment Guidelines for Livestock and Poultry (SVTG) in October last year. The guidelines emphasise minimising antibiotic use to prevent AMR in animals, mirroring similar efforts in human health. They provide symptomatic treatment guidance until a disease is laboratory-confirmed, ensuring minimal or no antibiotic use unless necessary. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines used to treat humans and animals. According to the World Health Organisation (WHO), around 10 million deaths are projected globally by 2050, with India expected to account for 2 million. In 2019, AMR was directly responsible for 1.27 million deaths globally, while 4.95 million were associated with drug-resistant infections. The WHO notes that the emergence and spread of AMR is accelerated by human activity — mainly the misuse and overuse of antimicrobials to treat, prevent, or control infections in humans, animals, and plants. Vegetables, poultry, and dairy products may contain antibiotic residues, which can enter the human bloodstream when consumed, further aggravating exposure. A recent study published in The Lancet Planetary Health stated that there are bidirectional associations between antibiotic consumption and AMR rates in humans and animals — that is, antibiotic use in animals can lead to AMR in humans, and vice versa. A separate study from 2015 estimated that nearly two-thirds of global antibiotic sales were for animal agriculture, with consumption projected to rise by another 67 per cent by 2030 due to increased demand for livestock products in low- and middle-income countries (LMICs). Coordinated action needed on new framework, says DCGI In a letter to all state and Union Territory (UT) drug controllers, Drug Controller General of India (DCGI) Rajeev Raghuvanshi called for coordinated action on AMU, specifically in the veterinary sector. The letter instructed all SLAs to nominate a nodal officer, not below the rank of assistant or joint drugs controller, to act as the point of contact for AMU data collection and coordination with the joint working group. It also asked state regulators to provide a comprehensive list of pharmaceutical companies involved in the manufacturing, distribution, and sale of veterinary antibiotics within their respective jurisdictions. In a separate letter dated 5 June, the DCGI also asked all zonal and sub-zonal offices of the CDSCO to share a list of approved drugs — including antibiotics, fixed drug combinations (FDCs), and their premixes — for veterinary use. A framework for AMU reporting is being seen as another key step to address AMR. Just last month, the central drug regulator released a draft guidance document for the safe disposal of unused or expired drugs, aimed at preventing AMR and other public health risks. The Centre had also urged pharmacists last year to dispense antibiotics only on the prescription of a qualified doctor, thereby limiting over-the-counter (OTC) sales. Under the Drugs and Cosmetics Rules, antibiotics are included in Schedule H — a list of drugs that may be sold by retail only on the prescription of a Registered Medical Practitioner (RMP).
Business Standard
7 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
News18
04-06-2025
- News18
‘Not A Regulatory Body': Indian Pharmacopoeia Clarifies It Only Sets Standards For Drugs, Doesn't Enforce Them
Last Updated: The clarification comes in the wake of increased global scrutiny of Indian-made drugs The Indian Pharmacopoeia Commission (IPC) has issued a clarification on its role amid growing concerns over impurities in medicines and the quality of drug manufacturing in India, News18 has learnt. In a notice issued by the apex authority titled 'Clarification on impurity limits published in the Indian Pharmacopoeia", it mentions that the IPC 'is in receipt of enquiries from various stakeholders…" and hence, it has been issuing the clarification. The IPC, which is responsible for setting the official quality standards for medicines in India, made it clear that while it defines the standards for impurities in drugs, it is not involved in approving or regulating new medicines. It said that responsibility lies with regulatory bodies like the CDSCO (Central Drugs Standard Control Organisation) and State Licensing Authorities. Both government departments, the Indian Pharmacopoeia Commission (IPC) and the apex regulatory agency, CDSCO, are headed by Dr Rajeev Singh Raghuvanshi. Impurities are small amounts of unwanted substances that may be present in a drug. While some impurities are acceptable within strict limits, their control is crucial to ensure the safety and effectiveness of medicines. The IPC sets impurity limits based on global standards and scientific data submitted by drug manufacturers. These limits are meant to serve as guidelines for making safe medicines, but final approval is always in the hands of the drug regulators. 'The IPC is an autonomous institution under the Ministry of Health & Family Welfare that is solely responsible for setting official drug standards… The IPC does not have any role in the regulatory review and approval of new drugs in India…the CDSCO and/or state licensing authorities are competent to take regulatory decisions." The clarification comes in the wake of increased global scrutiny of Indian-made drugs. Experts had raised questions about whether the IP includes adequate impurity limits for commonly used medicines. However, IPC, in the notice, has reiterated that it works in a consultative and advisory capacity, not as a regulator or certifying body. 'Impurities may be considered by the regulatory authority, provided it is supported with valid scientific justification and relevant data," it said. The notice, signed by Raghuvanshi, also pointed out that 'it is clarified that, in any case, the IPC does not have the mandate to approve or endorse impurity specifications…" Moreover, it added, 'the IPC, being a standard-setting organisation, is also not responsible to express opinion or recommendation in such regulatory matters." In fact, it has asked drug-makers and stakeholders 'to engage with the IPC by submitting scientific evidence to support monograph revisions, wherever required, to promote harmonisation with global standards". First Published: June 04, 2025, 10:26 IST
